
    
      Study participation for each patient will be up to a total of 46 weeks to 76 weeks including
      up to 10 days to 4 weeks of screening, 24 to 52 week treatment period on investigational
      medical product (IMP), and 20 weeks of post IMP treatment period.
    
  